trial

POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia

NCTId NCT01450514
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 7 (actual)
Sponsored by PharmaNeuroBoost N.V.
Primary completion 2012-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
7 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2012-03
Primary completion
2012-11
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Pipamperone

Sponsors

PharmaNeuroBoost N.V.Lead Sponsor

Investigators

1
Marc L. Steinberg, PH.D.Principal Investigator

Sites

1 total
Kortenberg, Belgium

Linked catalysts

1
POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Sc — primary completion2012-11

Facts & assertions

4 sourced
Enrollment
7
Phase
PHASE2
Primary Completion Date
2012-11
Status
COMPLETED
relationships
The graph out of here
drug
Pipamperone
drug
lead_sponsor
PharmaNeuroBoost N.V.
company
indication
Chronic Schizophrenia
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
investigator
Marc L. Steinberg, PH.D.
person